Turku, Finland, December 11^th 2019: Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women's health, today announces signing of a License and Collaboration Agreement with Novartis. The joint research collaboration is aimed at the identification of novel drugs for the treatment of chronic liver diseases. Novartis receives a worldwide exclusive license to drug candidates generated under the collaboration.

August 27^th 2019: Tonic App, the startup that developed the favourite mobile application of more than 12,000 medical doctors, has raised 3.5 million euros in a round co-led by Vesalius Biocapital Partners (Luxembourg) and Armilar Venture Partners (Portugal), joining Portugal Ventures and TheVentureCity.

Mecuris GmbH, a commercial-stage Munich-based medical technology startup focusing on the digitalization of prosthetics and orthotics, has been listed as one of the Best European MedTech Startups by Valuer. Vesalius Biocapital supports the innovative Mecuris approach since January 2019.

Turku, Finland, August 20^th 2019: Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women's health, today announces initiation of dosing in a Phase 1b clinical study in its lead endometriosis program with the aim to demonstrate Proof of Mechanism.

Turku, Finland, July 19^th 2019: Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women's health, today announces that Sunstone Life Science Ventures has made a €5 million investment in Forendo.

AMSTERDAM 18 July 2019 - DEARhealth, a health tech spin-out from the University of California, Los Angeles (UCLA), today announced a first closing of its Series A round with Philips Health Technology Ventures, Vesalius Biocapital III and Health Innovations. DEARhealth offers Artificial Intelligence (AI)-powered health pathways for chronic care.

Munich, 04.07.2019 - The Munich based medical technology startup Mecuris GmbH won industry expert Johannes Schneider Littfeld as Chairman of the Advisory Board. The company Mecuris offers a digital workshop for the creation and individualisation of prostheses and orthoses.

Luxembourg-Strassen, June 25, 2019 – Vesalius Biocapital III ('Vesalius'), the specialist life sciences venture capital investor, announces the final close of the VBC III fund securing EUR 120 million of equity commitments.

New York, Tuesday, 16^th April 2019: SWORD Health, a tech-enabled physical therapy provider, has raised $8 million in a series A investment round led by Khosla Ventures and several other prominent angel investors. It will allow SWORD to focus on bringing its technology to more patients' homes and expand its footprint in the U.S. market.

Tuesday, 09 April 2019 – Paralympic cyclist Denise Schindler is new brand ambassador for Medtech startup Mecuris. The Paralympic cyclist and current Vice World Champion will be the face of Mecuris for the next four years.